Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01166490 (Clinical Trial/ ASG-5ME)

Study Title
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma (NCT01166490)

Trial Description
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and tolerability in patients with relapsed or refractory gastric adenocarcinoma. This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Pancreatic or Gastric Adenocarcinoma
  • Interventions:
    • Drugs used in this trial
      • ASG-5ME
  • Phase: I
  • Enrollment: 51
  • Start: July 2010
  • Completion: July 2013
  • Last verified: August 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar